Huabang pharmaceutical "methylprednisolone sodium succinate for injection" obtained drug registration approval

In the evening of June 11, Huabang Yingtai announced that its wholly-owned subsidiary Chongqing Huabang pharmaceutical's "methylprednisolone sodium succinate for injection" had recently obtained the "drug registration approval document" issued by the State Food and drug administration It is reported that the drug is a general medicine with a market capacity of about 1.3 billion yuan in China According to the data, methylprednisolone sodium succinate for injection is widely used, and its indications mainly include: anti-inflammatory treatment, such as rheumatic diseases, severe skin diseases, allergic diseases (bronchial asthma, contact dermatitis, atopic dermatitis, allergic rhinitis, drug allergy, blood transfusion, acute laryngeal edema), severe acute and chronic eye allergy and Inflammation; critical stage of gastrointestinal diseases; respiratory diseases (aspiration pneumonia, etc.); edema state (for diuresis and proteinuria alleviation) Second, immunosuppressive therapy, including organ transplantation The third is to treat blood diseases and tumors Fourth, treat shock 5 Brain edema caused by tumor, and / or operation and radiotherapy; prevention of nausea and vomiting caused by cancer chemotherapy 6 Endocrine disorders In addition, because methylprednisolone sodium succinate for injection has the characteristics of good anti-inflammatory effect and quick onset, it is currently the mainstream corticosteroid injection in clinic, which is mainly used for the acute treatment of serious and critical diseases More than ten provinces have been included in the basic drug market Huabang Yingtai said that the approval of methylprednisolone sodium succinate for injection further enriched the company's product categories and had a positive significance for further optimizing the company's product structure However, the sales of the product is affected by uncertain factors such as the change of market environment, which is uncertain It is also understood that compound betamethasone injection, the first heavy-duty product imitated exclusively by Huabang Yingtai in China, is also expected to be approved in the near future, while moxifloxacin is more likely to be approved in the second half of the year.